News · 26 weeks57+40%
2026-03-012026-08-23
Mix2290d
- SEC Filings7(32%)
- Other5(23%)
- Insider5(23%)
- Earnings3(14%)
- Analyst2(9%)
Latest news
25 items- PRPulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to five new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. The equity awards were approved and issued on August 13, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4). Pulse has awarded inducement options to five new employees to purchase, in aggregate, up to 16,950 shares of Company common stock. The Company’s independent Comp
- ANALYSTNeedham initiated coverage on Pulse Biosciences with a new price targetNeedham initiated coverage of Pulse Biosciences with a rating of Buy and set a new price target of $58.00
- SECSEC Form 424B5 filed by Pulse Biosciences Inc424B5 - PULSE BIOSCIENCES, INC. (0001625101) (Filer)
- SECPulse Biosciences Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - PULSE BIOSCIENCES, INC. (0001625101) (Filer)
- SECSEC Form 10-Q filed by Pulse Biosciences Inc10-Q - PULSE BIOSCIENCES, INC. (0001625101) (Filer)
- SECPulse Biosciences Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - PULSE BIOSCIENCES, INC. (0001625101) (Filer)
- PRPulse Biosciences Reports Business Updates and Second Quarter 2026 Financial ResultsPulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced business updates and financial results for the second quarter ended June 30, 2026. Recent Business Highlights Cash and cash equivalents totaled $101.6 million as of June 30, 2026. During Q2 the Company raised $46.8 million in net proceeds through an at-the-market (ATM) program, raising approximately $13 million from insiders and the remaining $33.8 million in net proceeds from outside investors. Subsequent to the close of Q2, the Company raised an additional $10.7 million in net proceeds through the ATM and $1.8 million
- PRPulse Biosciences to Present at Canaccord Genuity’s 46th Annual Growth ConferencePulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced plans to participate in the upcoming Canaccord Genuity 46th Annual Growth Conference in Boston, MA. Pulse Biosciences’ Management is scheduled to present on Tuesday, August 11, at 2:30 pm ET. A live and recorded webcast of the fireside chat will be available on the "Events Calendar and Presentations" page of the company’s investor website at http://investors.pulsebiosciences.com/. About Pulse Biosciences® Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as
- SECPulse Biosciences Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - PULSE BIOSCIENCES, INC. (0001625101) (Filer)
- PRPulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal StudyPulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that the NANOPULSE-AF Study has surpassed its enrollment midpoint after commencing the study in April 2026. "We are very pleased by the strong enrollment trajectory in the NANOPULSE-AF study. Reaching this midpoint milestone so quickly reflects the enthusiasm of our investigational sites for this technology and its potential to deliver leading durability in pulmonary vein isolation, procedural efficiency and consistent safe and effective patient outcomes," said David Kenigsberg, MD, FACC, FHRS, Chief Medical Officer of Pul
- PRPulse Biosciences Schedules Second Quarter 2026 Financial Results Conference Call for August 6, 2026Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced it will report business updates and financial results for the second quarter 2026 after market close on Thursday, August 6, 2026. Company management will host a corresponding conference call to discuss business updates beginning at 1:30pm PT / 4:30pm ET.Investors interested in listening to the conference call may do so by dialing 1-800-715-9871 from the U.S. or 1-646-307-1963 internationally and providing Conference ID 3486060. A live and recorded webcast of the event will be available on the Pulse Biosciences Investors websi
- PRPulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to three new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. The equity awards were approved and issued on July 13, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).Pulse has awarded inducement options to three new employees to purchase, in aggregate, up to 9,000 shares of Company common stock. The Company’s independent Compensat
- INSIDERSEC Form 4 filed by Director Zanganeh Mahkam4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)
- INSIDERSEC Form 4 filed by Director Van Den Broek Richard4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)
- INSIDERSEC Form 4 filed by Director Duggan Robert W4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)
- INSIDERSEC Form 4 filed by Director Soni Manmeet Singh4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)
- INSIDERSEC Form 4 filed by Director Sainz Maria4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)
- SECPulse Biosciences Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - PULSE BIOSCIENCES, INC. (0001625101) (Filer)
- SECPulse Biosciences Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - PULSE BIOSCIENCES, INC. (0001625101) (Filer)
- PRPulse Biosciences, Inc. Announces Planned Redemption of WarrantsPulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that it intends to deliver an irrevocable notice of redemption, on or about June 10, 2026, to redeem the remaining common stock warrants issued by the Company as part of its July 3, 2024 rights offering. These outstanding common stock warrants (the "200% Warrants"), which were issued in the Company's 2024 rights offering (the "Rights Offering"), pursuant to the Company's Registration Statement on Form S-3, as amended (File No. 333-278494), may be exercised by the holders thereof until 5:00 p.m., Eastern time, on July 13, 202
- ANALYSTCanaccord Genuity initiated coverage on Pulse Biosciences with a new price targetCanaccord Genuity initiated coverage of Pulse Biosciences with a rating of Buy and set a new price target of $32.00
- PRPulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced plans to participate in the upcoming Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach, FL. Pulse Biosciences' Management is scheduled to present on Wednesday, June 10, at 10:00 am ET. A live and recorded webcast of the fireside chat will be available on the "Events Calendar and Presentations" page of the company's investor website at http://investors.pulsebiosciences.com/. About Pulse Biosciences® Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as w
- INSIDERAmendment: Director Duggan Robert W bought $12,999,988 worth of shares (660,233 units at $19.69), increasing direct ownership by 1% to 48,370,047 units (SEC Form 4)4/A - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)
- SECSEC Form 10-Q filed by Pulse Biosciences Inc10-Q - PULSE BIOSCIENCES, INC. (0001625101) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Pulse Biosciences IncSCHEDULE 13D/A - PULSE BIOSCIENCES, INC. (0001625101) (Subject)
PLSE FAQ
7 questionsWhat does Pulse Biosciences Inc do?
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue primarily for dermatology applications by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.Where does PLSE stock trade?
Pulse Biosciences Inc (PLSE) is listed on NASDAQ.What sector and industry is PLSE in?
Pulse Biosciences Inc operates in the Health Care sector, Medical/Dental Instruments industry.When did Pulse Biosciences Inc go public?
Pulse Biosciences Inc (PLSE) completed its IPO in 2016.What are analysts saying about PLSE?
Pulse Biosciences Inc has had 7 recent analyst actions on file. The most recent action was from Needham: Buy on 2026-08-17. Recent price targets range from $2000.00 to $4300.00.What companies are similar to PLSE?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare PLSE side-by-side with any of them on Quantisnow.How can I track PLSE on Quantisnow?
Quantisnow aggregates Pulse Biosciences Inc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PLSE to receive live email and push alerts on every new disclosure.